Development of Engager T cells for immunotherapy of lung cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09218
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Osaka University
• Principal Investigator: IWAHORI KOTA 大阪大学, 医学系研究科, 特任講師(常勤) (80566448)
• Project Period (FY): 2015-10-21 – 2018-03-31
• Keywords: がん免疫療法

Outline of Final Research Achievements

We generated T cells expressing a secretable bispecific T-cell engager (Engager-T cells) for cancer immunotherapy. For the development of Engager T cells against lung cancer, we evaluated detailed immunological aspects in clinical specimens from non-small cell lung cancer (NSCLC) patients. We analyzed the immune profiles and T cell cytotoxicity of lung tumor tissue from NSCLC patients. By using bispecific T-cell engager (BiTE) to assess the cytotoxicity of T cells, we found that the cytotoxicity of tumor-infiltrated T cells correlated with immune profiles and smoking status of NSCLC patients. These results imply predictive biomarkers for the efficacy of Engager-T cells.

Free Research Field

呼吸器内科学